These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23670590)

  • 1. P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents.
    O'Brien FE; O'Connor RM; Clarke G; Dinan TG; Griffin BT; Cryan JF
    Neuropsychopharmacology; 2013 Oct; 38(11):2209-19. PubMed ID: 23670590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram.
    O'Brien FE; O'Connor RM; Clarke G; Donovan MD; Dinan TG; Griffin BT; Cryan JF
    Behav Brain Res; 2014 Mar; 261():17-25. PubMed ID: 24280122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of P-glycoprotein enhances transport of imipramine across the blood-brain barrier: microdialysis studies in conscious freely moving rats.
    O'Brien FE; Clarke G; Fitzgerald P; Dinan TG; Griffin BT; Cryan JF
    Br J Pharmacol; 2012 Jun; 166(4):1333-43. PubMed ID: 22250926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic P-glycoprotein inhibition increases the brain concentration of escitalopram: potential implications for treating depression.
    O'Brien FE; Moloney GM; Scott KA; O'Connor RM; Clarke G; Dinan TG; Griffin BT; Cryan JF
    Pharmacol Res Perspect; 2015 Dec; 3(6):e00190. PubMed ID: 27022464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of P-glycoprotein to bunitrolol efflux across blood-brain barrier.
    Matsuzaki J; Yamamoto C; Miyama T; Takanaga H; Matsuo H; Ishizuka H; Kawahara Y; Kuwano M; Naito M; Tsuruo T; Sawada Y
    Biopharm Drug Dispos; 1999 Mar; 20(2):85-90. PubMed ID: 10206323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood-brain barrier in vivo.
    Bundgaard C; Eneberg E; Sánchez C
    Neuropharmacology; 2016 Apr; 103():104-11. PubMed ID: 26700248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.
    Agarwal S; Sane R; Gallardo JL; Ohlfest JR; Elmquist WF
    J Pharmacol Exp Ther; 2010 Jul; 334(1):147-55. PubMed ID: 20421331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).
    Mittapalli RK; Vaidhyanathan S; Sane R; Elmquist WF
    J Pharmacol Exp Ther; 2012 Jul; 342(1):33-40. PubMed ID: 22454535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans.
    Muzi M; Mankoff DA; Link JM; Shoner S; Collier AC; Sasongko L; Unadkat JD
    J Nucl Med; 2009 Aug; 50(8):1267-75. PubMed ID: 19617341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling cyclosporine A inhibition of the distribution of a P-glycoprotein PET ligand, 11C-verapamil, into the maternal brain and fetal liver of the pregnant nonhuman primate: impact of tissue blood flow and site of inhibition.
    Ke AB; Eyal S; Chung FS; Link JM; Mankoff DA; Muzi M; Unadkat JD
    J Nucl Med; 2013 Mar; 54(3):437-46. PubMed ID: 23359659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of P-glycoprotein Inhibition on the Penetration of Ceftriaxone Across the Blood-Brain Barrier.
    Shan Y; Cen Y; Zhang Y; Tan R; Zhao J; Nie Z; Zhang J; Yu S
    Neurochem Res; 2022 Mar; 47(3):634-643. PubMed ID: 34694535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo evidence for amphotericin B as a P-glycoprotein substrate on the blood-brain barrier.
    Wu JQ; Shao K; Wang X; Wang RY; Cao YH; Yu YQ; Lou JN; Chen YQ; Zhao HZ; Zhang QQ; Weng XH; Jiang C; Zhu LP
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4464-9. PubMed ID: 24867970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
    Uchida Y; Ohtsuki S; Kamiie J; Terasaki T
    J Pharmacol Exp Ther; 2011 Nov; 339(2):579-88. PubMed ID: 21828264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of verapamil on the pharmacokinetics of the pan-HER tyrosine kinase inhibitor neratinib in rats: the role of P-glycoprotein-mediated efflux.
    Qi D; Dou Y; Zhang W; Wang M; Li Y; Zhang M; Qin J; Cao J; Fang D; Ma J; Yang W; Xie S; Sun H
    Invest New Drugs; 2023 Feb; 41(1):13-24. PubMed ID: 36331675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates.
    Damont A; Goutal S; Auvity S; Valette H; Kuhnast B; Saba W; Tournier N
    Eur J Pharm Sci; 2016 Aug; 91():98-104. PubMed ID: 27283486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of P-glycoprotein in intestinal transport versus the BBB transport of tetraphenylphosphonium.
    Swed A; Eyal S; Madar I; Zohar-Kontante H; Weiss L; Hoffman A
    Mol Pharm; 2009; 6(6):1883-90. PubMed ID: 19722701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered brain concentrations of citalopram and escitalopram in P-glycoprotein deficient mice after acute and chronic treatment.
    Karlsson L; Carlsson B; Hiemke C; Ahlner J; Bengtsson F; Schmitt U; Kugelberg FC
    Eur Neuropsychopharmacol; 2013 Nov; 23(11):1636-44. PubMed ID: 23428338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice.
    Uhr M; Grauer MT
    J Psychiatr Res; 2003; 37(3):179-85. PubMed ID: 12650738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective analysis of P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier in humans.
    Sugimoto H; Hirabayashi H; Amano N; Moriwaki T
    Drug Metab Dispos; 2013 Apr; 41(4):683-8. PubMed ID: 23340958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
    Sane R; Agarwal S; Mittapalli RK; Elmquist WF
    J Pharmacol Exp Ther; 2013 Apr; 345(1):111-24. PubMed ID: 23397054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.